에베로리무스
|
|
에베로리무스 속성
- 녹는점
- NA
- 끓는 점
- 998.7±75.0 °C(Predicted)
- 밀도
- 1.18±0.1 g/cm3(Predicted)
- 인화점
- 2℃
- 저장 조건
- -20°C
- 용해도
- DMSO(최대 100mg/ml) 또는 에탄올(최대 100mg/ml)에 용해됩니다.
- 물리적 상태
- 고체
- 물리적 상태
- 단단한 모양
- 산도 계수 (pKa)
- 10.40±0.70(Predicted)
- 색상
- 하얀색
- 수용성
- 디메틸설폭사이드, 에탄올 및 클로로포름에 용해됩니다. 물에 약간 용해됩니다.
- 안정성
- 흡습성
- InChIKey
- HKVAMNSJSFKALM-GKUWKFKPSA-N
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
위험품 표기 | T,Xn,F | ||
---|---|---|---|
위험 카페고리 넘버 | 48/25-36-20/21/22-11 | ||
안전지침서 | 45-36/37-26-16 | ||
유엔번호(UN No.) | UN 1648 3 / PGII | ||
WGK 독일 | 2 | ||
F 고인화성물질 | 10 | ||
HS 번호 | 29349990 | ||
유해 물질 데이터 | 159351-69-6(Hazardous Substances Data) |
그림문자(GHS): | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
신호 어: | Warning | ||||||||||||||||||||||||||||
유해·위험 문구: |
|
||||||||||||||||||||||||||||
예방조치문구: |
|
에베로리무스 C화학적 특성, 용도, 생산
용도
에베로 리무스는 신호 전달 억제제라고하는 치료 유형입니다. 신호 전달 저해제는 세포 내에서 신호가 성장하고 분열되도록하는 신호를 차단합니다.에버 롤리 무스는 mTOR라는 특정 단백질을 제대로 작동시키지 못하도록 막습니다. mTOR는 암세포가 자라는 다른 단백질을 조절합니다. 따라서 는 암의 성장을 막는데 도움이됩니다.독성
에베로 리무스를 복용하면 박테리아, 바이러스 및 곰팡이에 의한 감염을 막을 수있는 능력이 떨어지고 심각한 또는 생명을 위협하는 감염 위험을 높일 수 있습니다.개요
Everolimus, an oral immunosuppressant for the treatment of kidney and heart transplant rejection, is the 40-O-(2-hydroxyethyl) derivative of rapamycin. It has immunosuppressive properties similar to those of rapamycin, but with improved pharmacokinetic profile. Everolimus, like rapamycin, is a proliferation signal inhibitor that exerts its immunosuppressive effect by inhibiting the activation of p70 S6 kinase, thereby blocking growth factor-driven proliferation of T cells, B cells and vascular smooth muscle cells, and arresting cell cycle at the G1 phase. Inhibition of p70 S6 kinase activation by everolimus and rapamycin is mediated by their binding to FKBP12 (FK506 binding-protein 12). Everolimus inhibits FK506 binding to FKBP12 with an IC50 of 1.8–2.6 nM, and it is about 3- to 5-fold less potent than rapamycin (IC50=0.4–0.9 nM). The in vitro immunosuppressive activity of everolimus is also slightly less than that of rapamycin as demonstrated in a mixed lymphocyte reaction (MLR) assay (IC50=0.2–1.6 nM versus 0.07–0.5 nM, respectively) and in antigen-specific human helper T-cell clones (IC50=0.05–0.17nM versus 0.014–0.37nM, respectively). However, the in vivo immunosuppressive activity of oral everolimus 1–5 mg/ kg/day is similar to that of rapamycin at equivalent doses in rat models of renal or cardiac transplantation, localized graft-versus-host disease, and autoimmune glomerulonephritis. The recommended dosage of everolimus is 0.75 mg twice daily, and it is used in combination with cyclosporine microemulsion and corticosteroids.화학적 성질
Off White Solid용도
Everolimus (IX) (SDZ-RAD), was developed by Novartis as an immunosuppressant to be used in conjunction with cyclosporin in transplantation allograft rejection and was recently approved in the US in 2003. Another natural product that had been approved for use in transplantation is rapamycin (sirolimus) as an inejectable agent. In an attempt to develop an orally bioavailable immunosuppressant agent, many companies attempted modification of rapamycin itself.정의
ChEBI: Everolimus is a macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted into the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent. It has a role as an antineoplastic agent, an immunosuppressive agent, a mTOR inhibitor, an anticoronaviral agent and a geroprotector. It is a primary alcohol, a secondary alcohol, an ether, a cyclic ketone, a cyclic acetal and a macrolide lactam. It is functionally related to a member of sirolimus.일반 설명
Everolimus, sold under trade names including Zortress?, Certican, and Afinitor?, is an immunosuppressant drug used to prevent rejection of organ transplants and to treat renal cell cancer and other tumors. This Certified Spiking Solution? is suitable as starting material for calibrators, controls, or linearity standards for therapeutic drug monitoring or clinical and diagnostic testing of everolimus in patient whole blood samples by LC-MS/MS.에베로리무스 준비 용품 및 원자재
원자재
준비 용품
에베로리무스 공급 업체
글로벌( 550)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Finetech Industry Limited | +86-27-87465837 +8618971612321 |
info@finetechnology-ind.com | China | 9602 | 58 |
ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 |
ivan@atkchemical.com | China | 32760 | 60 |
AFINE CHEMICALS LIMITED | +86-0571-85134551 |
info@afinechem.com | China | 15395 | 58 |
Seasons Biotechnology Co., Ltd. | +86-0576-89232655 +86-13566878689 |
info@seasonsbio.com | China | 47 | 58 |
BOC Sciences | 16314854226; +16314854226 |
inquiry@bocsci.com | United States | 19743 | 58 |
Henan Bao Enluo International TradeCo.,LTD | +86-17331933971 +86-17331933971 |
deasea125996@gmail.com | China | 2503 | 58 |
Shaanxi Haibo Biotechnology Co., Ltd | +undefined18602966907 |
qinhe02@xaltbio.com | China | 1000 | 58 |
Capot Chemical Co.,Ltd. | 571-85586718 +8613336195806 |
sales@capotchem.com | China | 29798 | 60 |
Beijing Cooperate Pharmaceutical Co.,Ltd | 010-60279497 |
sales01@cooperate-pharm.com | CHINA | 1811 | 55 |
Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21668 | 55 |
에베로리무스 관련 검색:
Rapamycin
Argatroban
Everolimus Impurity 1
Etofenamate
Etoposide
Everolimus O-Ethyl Impurity
Exemestane
Everolimus Ring-Opening Impurity
Everolimus Related Compound 3
2,6-di-tert-butyl-4-methylene-2,5-cyclohexadienone
2-(tert-butyldiMethylsilyl )oxyl alcohol trifluorin Methanesulfonate
Ethyleneglycol bistriflate
Methanesulfonic acid, trifluoro-, 2-hydroxyethyl ester
EveroliMus iMpurity
EveroliMus-d4
BIS(T-BUTYLDIMETHYLSILOXY)ETHANE
Everolimus 28-Ethylhydroxy Impurity
Everolimus Impurity 2